Understanding how immunizations stimulate protection begins with a deep dive into the mechanisms of vaccine action & immune response. Cellular and humoral components interact in finely tuned sequences, with antigen presentation, cytokine signaling, and T and B cell activation forming the foundation of long-term immunity. These mechanisms vary depending on the nature of the vaccine platform and the immune status of the recipient. Research now extends beyond classical pathways, incorporating innate immune training, epigenetic reprogramming, and memory imprinting. A more nuanced grasp of these biological processes enables the design of next-generation vaccines that are both targeted and durable. Ongoing investigations also explore how variations in host genetics, microbiota, and previous exposures affect immunologic outcomes. Clarifying these relationships is key to addressing population-level variability in vaccine efficacy and safety, ultimately guiding more personalized and effective immunization strategies.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States